Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
Probiotic potential of SNZ 1969 has been studied in subjects with constipation predominant irritable bowel syndrome (IBS-C) and diarrhoea predominant irritable bowel syndrome
Latest study shows that Hyderabad-based Sanzyme Biologics’s Bacillus coagulans SNZ 1969 (Weizmannia coagulans SNZ 1969), a natural spore forming probiotic strain over five decades of use and more than 30 human studies across age groups, is found to be effective in managing Irritable bowel syndrome (IBS) symptoms. This study is unique as it covers both the IBS-Diarrhoea and IBS-Constipation groups with larger number of subjects.
IBS is one of the most common disorders of gut-brain interaction, estimated to affect around 11% people globally. The outcome of this study will be significant to supplement manufacturers as it can help design products to address consumer need for managing IBS symptoms with a scientifically studied probiotic strain.
This study was conducted at Apollo Hospitals, Hyderabad, India and published in the International Journal of Basic & Clinical Pharmacology.
The same strain has been studied earlier for gastrointestinal discomfort, intestinal motility and intermittent constipation among healthy subjects.
Sanzyme Biologics was incorporated in 1969 as Uni-Sankyo. Over the last five decades Sanzyme Biologics established its strength in probiotics by developing scientifically studied and well-documented probiotic strains, pioneered their applications beyond human health into aqua, veterinary, poultry and bioremediation. Sanzyme Biologics has market presence in over 40 countries.
Image credit- shutterstock